Immunohistochemical and morphometric studies of the fetal pancreas in diabetic pregnant rats. Effects of insulin administration.
Maternal diabetes influences fetal pancreas development. As there are some controversial reports, we studied the morphometric changes of the fetal insular pancreas and insulin immunostain of beta cells as well as the proliferative activity of insular cells in 21-day-old fetuses from control, diabetic, and insulin-treated diabetic pregnant rats.



Streptozotocin was injected into 7-day-pregnant rats (controls were not injected). Some rats were either left untreated (diabetic) or injected with insulin. Animals were killed at 21 days of gestation. Fetal pancreas were fixed in toto for the morphometry and immunohistochemistry studies using anti-insulin, anti-Ki-67 and anti-proliferating cell nuclear antigen (PCNA) antibodies.



Diabetic status was determined by measuring maternal and fetal serum glucose and insulin levels. The morphometric studies showed hyperplasia of the diabetic fetal insular tissue which had not been normalized by insulin therapy. Diabetes caused an increase of both insulin-positive and insulin-negative cells. The increase in insulin-positive cells was not corrected by insulin treatment, although the number of non-beta cells became normal. The nuclear area in beta cells increased in diabetic rats but was not corrected by insulin. The cytoplasmic area decreased in diabetic rats and was normalized by insulin administration. Diabetes increased the expression of the nuclear antigen Ki-67 in fetal insular pancreas, and insulin treatment returned it to the normal state.



Maternal diabetes leads to hyperstimulation of fetal beta cells, with increased proliferative activity. Insulin administration to the dams corrects some of the changes observed.
Calvo
R M
RM
Instituto de Investigaciones Biomédicas (CSIC), Madrid, Spain.
Forcen
R
R
Obregon
M J
MJ
Escobar del Rey
F
F
Morreale de Escobar
G
G
Regadera
J
J
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000378:metabolism; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000378:metabolism; D007124:Immunoenzyme Techniques; D007328:Insulin / Q000008:administration & dosage* / Q000378:metabolism; D007515:Islets of Langerhans / Q000187:drug effects / Q000196:embryology* / Q000378:metabolism*; D019394:Ki-67 Antigen / Q000378:metabolism; D011247:Pregnancy; D011254:Pregnancy in Diabetics; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D019394:Ki-67 Antigen; D018809:Proliferating Cell Nuclear Antigen